FTH, US81728A2078

Faeth Therapeutics stock heads into October 6 cancer event

Published on 10/05/2026 at 14:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Faeth Therapeutics stock was last at USD 28.35 on October 2, while the company prepares an October 6 KOL event. Q2 net loss reached USD 16.0 million.

FTH, US81728A2078, Illustration mit AI erstellt.

Faeth Therapeutics stock (ISIN US81728A2078) was last at USD 28.35 on Nasdaq on October 2, 2026, with a market capitalization of USD 730.8 million and a 0.28 percent gain from the prior close. The next company milestone is a virtual key opinion leader event on October 6, 2026, centered on PIKTOR and endometrial cancer, according to Business Wire.

October 6 event centers on PIKTOR

The event starts at 10:00 a.m. ET and will feature Marcus Goncalves, a scientific co-founder and physician, alongside company management. Business Wire said the discussion will cover the PAM pathway, the dose and schedule used in the Phase 2 trial, and prior Phase 1b clinical data.

Faeth is developing PIKTOR as an oral combination of serabelisib and sapanisertib. The Phase 2 study targets second-line advanced endometrial cancer, while a separate Phase 1b/2 study is evaluating the program in HR-positive, HER2-negative advanced breast cancer, according to Business Wire.

Losses keep the clinical story in view

Faeth recorded a net loss of USD 16.0 million in the second quarter of 2026, compared with USD 4.9 million in the second quarter of 2025, according to RTTNews. The same quarter produced diluted EPS of USD -2.84 against a consensus estimate of USD -3.0784, while revenue was USD 0.00, as reported by Nasdaq.

That combination leaves the October event carrying more importance for the share story than near-term revenue. Management has said topline Phase 2 data are anticipated by year-end 2026, making clinical progress the central valuation reference for this development-stage biotechnology company.

Analyst targets sit above Nasdaq price

Nasdaq reported an aggregate analyst profile of 6 Strong Buy, 8 Buy and 1 Hold recommendations as of September 1, 2026. The consensus mean target was USD 55.73 and the median was USD 56.10 as of August 28, 2026; the mean target lies 96.6 percent above the October 2 price of USD 28.35.

Stock remains below its yearly high

Faeth Therapeutics stock was last at USD 28.35 on Nasdaq on October 2, 2026, within a 52-week range of USD 7.45 to USD 42.14. Trading volume was 187,922 shares, while the October 2 market capitalization stood at USD 730.8 million.